ART

EQS-News: Daldrup & Söhne AG welcomes BMWK and KfW initiative on insurance solutions for deep boreholes

Retrieved on: 
Wednesday, April 10, 2024
Transfer, ART, Daldrup, Electricity, Environment, Geothermal energy, Development, Frankfurt Stock Exchange, AG, WKN, Risk, Copper, EDS, Gold, Water extraction, Water purification, Groundwater, Insurance, Plant, Drinking, BMWK, Raw material, Renewable energy

Oberhaching / Ascheberg, 25 March 2024 - Daldrup & Söhne AG (ISIN DE0007830572), drilling technology and geothermal specialist, supports the initiative of the Federal Ministry of Economics and Technology (BMWK) and the KfW development bank to establish a state-supported insurance solution for the so-called exploration risk for deep geothermal wells.

Key Points: 
  • Oberhaching / Ascheberg, 25 March 2024 - Daldrup & Söhne AG (ISIN DE0007830572), drilling technology and geothermal specialist, supports the initiative of the Federal Ministry of Economics and Technology (BMWK) and the KfW development bank to establish a state-supported insurance solution for the so-called exploration risk for deep geothermal wells.
  • KfW loans can already be applied for the realisation of deep geothermal projects, but the securing of the discovery has not yet been included.
  • Andreas Tönies, CEO of Daldrup & Söhne AG, welcomes the BMWK's plans to insure exploration risks: "A state-backed insurance solution will remove a major hurdle for municipal and private clients of deep geothermal projects.
  • Together with well-known partners in the insurance industry, Daldrup & Söhne AG has developed a concept to cover exploration risks during the construction of deep geothermal projects.

Hamilton Thorne Ltd. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Wednesday, April 10, 2024
ART, OTC Markets Group, HTL, Metro Toronto Convention Centre, Software, Conference, TSX, Research

Beverly, Massachusetts--(Newsfile Corp. - April 10, 2024) - Hamilton Thorne Ltd. (TSX: HTL) (OTC Pink: HTLZF), Hamilton Thorne Ltd. a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets., will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.

Key Points: 
  • Beverly, Massachusetts--(Newsfile Corp. - April 10, 2024) - Hamilton Thorne Ltd. (TSX: HTL) (OTC Pink: HTLZF), Hamilton Thorne Ltd. a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets., will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

Retrieved on: 
Wednesday, April 3, 2024
ART, IgA nephropathy, Congress, Quality of life (healthcare), Patient, SAN, Kidney failure, Immunoglobulin A, RAAS, FSGS, PROTECT, Focal segmental glomerulosclerosis, Abstract, Kidney disease, Therapy, WCN, Proteinuria, ANNA, Communications satellite

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina, on April 13-16, 2024, and the American Nephrology Nurses Association (ANNA) National Symposium in Orlando, Florida, on April 14-17, 2024.

Key Points: 
  • SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina, on April 13-16, 2024, and the American Nephrology Nurses Association (ANNA) National Symposium in Orlando, Florida, on April 14-17, 2024.
  • At WCN, the Company will present subgroup analyses of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) showing the treatment effect across participants with different levels of baseline proteinuria.
  • At ANNA, the Company will present additional insights from the HONUS trial, including health-related quality of life (HRQoL) data and the humanistic burden experienced by patients with IgAN and focal segmental glomerulosclerosis (FSGS).
  • “The data we are presenting at WCN and ANNA reinforce the wealth of evidence supporting FILSPARI’s profile to become an effective foundational treatment replacing RAAS inhibition, with the potential to reduce the lifetime risk of kidney failure for patients with IgAN,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics.

WISeKey Subsidiary WISe.ART Honors Marina Fita at Mayte Spínola Gold Medal Ceremony

Retrieved on: 
Wednesday, April 3, 2024
ART, Bärenreiter, Metropolitan Opera House, Spinola, Partnership, Internet of things, Criminology, University, WIHN, WKEY, Singing, Music

At the event, Marina Fita was awarded the Spinola medal by Mayte, an incredible honor presented to her by its founder.

Key Points: 
  • At the event, Marina Fita was awarded the Spinola medal by Mayte, an incredible honor presented to her by its founder.
  • Marina’s musical academic journey began in 2008 at the Velluters Professional Conservatory of Music in Valencia, specializing in piano.
  • She went on to obtain the title of Technician in Professional Musical Education in Piano and Lyric Singing, also receiving an honorable mention in Lyric Singing.
  • WISe.ART’s event allowed Marina to present her talent to a distinguished audience, further establishing herself as a promising soprano.

University of Québec at Trois-Rivières (UQTR) and the Province of Quebec invest over $900,000 in ARHT hologram technology for groundbreaking study

Retrieved on: 
Tuesday, April 2, 2024
ART, University, UQTR, OTCQB

This research study will utilize ARHT’s suite of technology for multiple locations throughout the Province of Quebec and has commenced in March 2024.

Key Points: 
  • This research study will utilize ARHT’s suite of technology for multiple locations throughout the Province of Quebec and has commenced in March 2024.
  • “The hologram is undoubtedly an avenue at the cutting edge of communication technologies, training, and distance education.
  • Its potential must be explored, hence the innovative nature of our research project.
  • I salute ARHT Media whose expertise and products will allow us to experiment and document new training practices in Quebec,” stated Ph.D. Professor-Researcher France Lafleur of UQTR.

ARHT and Provision Events Team Up to Enhance Fan Engagement at Hoag Classic PGA Tour Champions Event

Retrieved on: 
Thursday, March 28, 2024
ART, Compass, Education, Magic, Kiosk, Hoag Classic, Creativity, PGA, Nursing, Provision

This collaborative effort was set to redefine fan experiences at this year’s PGA Tour Champions Event, the Hoag Classic 2024.

Key Points: 
  • This collaborative effort was set to redefine fan experiences at this year’s PGA Tour Champions Event, the Hoag Classic 2024.
  • "Provision Events is extremely proud to once again partner with the title sponsor of the Hoag Classic, incorporating ARHT's cutting-edge holographic technology to enhance fan engagement and deliver the Hoag on-course fan hospitality experience," stated Jordy Watts, Client Services Manager at Provision Events.
  • "We were thrilled to collaborate with Provision Events and Hoag in creating an immersive experience for the Hoag Classic PGA Champions event.
  • This activation not only enhanced fan engagement but also highlighted the exceptional quality of the Hoag Fan Experience.

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Retrieved on: 
Monday, March 25, 2024
ART, Research, Depression, Neuropathic pain, Argyreia nervosa, Weight gain, Cachexia, Anxiety, Cancer, IND, Investment, Safety, Pain, FDA, Cannabidiol, Pharmaceutical industry

SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2023 and provided a business update.

Key Points: 
  • SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2023 and provided a business update.
  • “We made substantial progress on multiple programs last year,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • Cash and Investments: Cash and investments totalled $10.4 million as of December 31, 2023.
  • R&D Expenses: Research and development expenses were $5.7 million for the year ended December 31, 2023, compared to $4.3 million for the same period in 2022.

Hamilton Thorne to Announce Q4 and Full Year 2023 Financial Results and Hold Conference Call on March 27, 2024

Retrieved on: 
Thursday, March 21, 2024
ART, HTL, Conference, TSX, Research, EDT, Software, Cryptocurrency

and TORONTO, March 21, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three and twelve months ended December 31, 2023 before market open on Wednesday, March 27, 2024.

Key Points: 
  • and TORONTO, March 21, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three and twelve months ended December 31, 2023 before market open on Wednesday, March 27, 2024.
  • The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.ltd and on www.sedar.com .
  • The Company will follow with a conference call on the same day at 9:00 a.m. EDT to review highlights of the results.
  • All interested parties are welcome to join the conference call by dialing toll free 1-833-366-1126 in North America, or 1-412-317-0703 from other locations, and requesting the “Hamilton Thorne Conference Call.” The Company’s updated investor presentation and a recording of the call will be available on Hamilton Thorne’s website shortly after the call.

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Retrieved on: 
Thursday, March 21, 2024
ART, Obstetrics, Fireside, Gynaecology, Infertility, Case Western Reserve University, IVF, Climate, University, Woman, Reproductive biology, FDA

Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here.

Key Points: 
  • Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here.
  • will focus on the current treatment options in the infertility services market, including Femasys’ FDA-authorized FemaSeed device for intratubal insemination.
  • Ms. Lee-Sepsick is the founder of Femasys and has nearly three decades of experience as a senior executive in the medical technology industry.
  • She is the lead inventor of the technologies at Femasys and remains committed to advancing much needed technology in women’s health.

WISe.ART to Host the Prestigious ProArte y Cultura Mayte Spínola Gold Medals 2023 at the Iconic Nasdaq Building in New York City on April 1, 2024

Retrieved on: 
Tuesday, March 19, 2024
ART, Organization, Nasdaq MarketSite, Partnership, Internet of things, Education, Duke, City, Heart, Music, WIHN, WKEY, 4 Times Square

This year’s event is particularly momentous as it celebrates the 80th anniversary of Mayte Spínola, painter and sculptor a seminal figure in the arts and culture sector and the founder of the Pro Arte y Cultura Group.

Key Points: 
  • This year’s event is particularly momentous as it celebrates the 80th anniversary of Mayte Spínola, painter and sculptor a seminal figure in the arts and culture sector and the founder of the Pro Arte y Cultura Group.
  • Jointly organized by Wise.ART and ProArte y Cultura the event will honor individuals and organizations that have shown an outstanding dedication to various disciplines, including education, philanthropy, industry, fashion, and music.
  • The Mayte Spínola Gold Medals 2023 will recognize the achievements of notable figures such as the Duques de Soria Foundation, Alicia Habsburg-Lorraine, S.A.R.
  • Since its inception in 1990, the Pro Arte y Cultura Group, founded by Mayte Spínola, has been instrumental in organizing exhibitions and advocating for the arts across various European cities.